Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor

Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, MTFS, N-7489 Trondheim, Norway. randi.u.holt@medisin.ntnu.no

BACKGROUND AND OBJECTIVES: Multiple myeloma is characterized by an accumulation of malignant plasma cells in the bone marrow. Inside the bone marrow, adhesion of myeloma cells to extracellular matrix proteins such as fibronectin may promote cell survival and induce drug resistance. In this work we examined the effect of hepatocyte growth factor (HGF) on the adhesion of myeloma cells and the signaling pathways involved. DESIGN AND METHODS: Cell adhesion experiments were performed with the human myeloma cell line INA-6 and primary myeloma cells. The HGF signaling pathway was studied in INA-6 cells with the use of antibodies against VLA-4 integrin, and with inhibitors of various intracellular signaling molecules. RESULTS: We found that HGF stimulated adhesion of myeloma cells to fibronectin. This event was dependent on the alpha4 and beta1 integrin subunits (VLA-4), but HGF did not increase the expression of integrins on the cell surface. Our findings suggest that HGF promotes myeloma cells to adhere via activation of the phosphatidylinositol 3-kinase (PI3K) pathway independently of AKT, but possibly through the involvement of nuclear factor kappa B (NF-kappaB). INA-6 cells adhered to fibronectin after stimulation by insulin-like growth factor or stromal cell-derived factor 1alpha, but this adhesion was less dependent on PI3K than HGF-mediated adhesion. INTERPRETATION AND CONCLUSIONS: his work points to HGF as a pro-adhesive factor in cell adherence to the bone marrow matrix protein fibronectin, an event known to promote cancer cell survival and drug resistance. Inhibiting HGF, its receptor c-Met or the VLA-4 integrin may be beneficial to the myeloma patient.

This article has been cited by other articles:

				R. U. Holt, U.-M. Fagerli, V. Baykov, T. B. Ro, H. Hov, A. Waage, A. Sundan, and M. Borset Hepatocyte growth factor promotes migration of human myeloma cells Haematologica, April 1, 2008; 93(4): 619 - 622. [Abstract] [Full Text] [PDF]

				U.-M. Fagerli, R. U. Holt, T. Holien, T. K. Vaatsveen, F. Zhan, K. W. Egeberg, B. Barlogie, A. Waage, H. Aarset, H. Y. Dai, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells Blood, January 15, 2008; 111(2): 806 - 815. [Abstract] [Full Text] [PDF]

				S. T. Pals, D. J. J. de Gorter, and M. Spaargaren Lymphoma dissemination: the other face of lymphocyte homing Blood, November 1, 2007; 110(9): 3102 - 3111. [Abstract] [Full Text] [PDF]

				C. M. Stellrecht, C. J. Phillip, F. Cervantes-Gomez, and V. Gandhi Multiple Myeloma Cell Killing by Depletion of the MET Receptor Tyrosine Kinase Cancer Res., October 15, 2007; 67(20): 9913 - 9920. [Abstract] [Full Text] [PDF]

				T. Standal, N. Abildgaard, U.-M. Fagerli, B. Stordal, O. Hjertner, M. Borset, and A. Sundan HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma Blood, April 1, 2007; 109(7): 3024 - 3030. [Abstract] [Full Text] [PDF]

				D. Generali, S. B. Fox, A. Berruti, J. W. Moore, M. P. Brizzi, N. Patel, G. Allevi, S. Bonardi, S. Aguggini, A. Bersiga, et al. Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer Clin. Cancer Res., January 15, 2007; 13(2): 550 - 558. [Abstract] [Full Text] [PDF]